Biologic and therapeutic role of HER2 in cancer
S Menard, SM Pupa, M Campiglio, E Tagliabue - Oncogene, 2003 - nature.com
Overexpression of the human epidermal growth factor-2 (HER2) oncogene in human breast
carcinomas has been associated with a more aggressive course of disease. The reason for …
carcinomas has been associated with a more aggressive course of disease. The reason for …
Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors
LN Klapper, MH Kirschbaum, M Seta… - Advances in cancer …, 1999 - Elsevier
Publisher Summary Carcinoma, cancer of epithelial cells, is a major cause of morbidity and
mortality. Clonal fixation and propagation of oncogenic genetic changes, sporadically …
mortality. Clonal fixation and propagation of oncogenic genetic changes, sporadically …
Engineering hybrid exosomes by membrane fusion with liposomes
YT Sato, K Umezaki, S Sawada, S Mukai, Y Sasaki… - Scientific reports, 2016 - nature.com
Exosomes are a valuable biomaterial for the development of novel nanocarriers as
functionally advanced drug delivery systems. To control and modify the performance of …
functionally advanced drug delivery systems. To control and modify the performance of …
Engagement of the OX-40 receptor in vivo enhances antitumor immunity
AD Weinberg, MM Rivera, R Prell, A Morris… - The Journal of …, 2000 - journals.aai.org
Abstract The OX-40 receptor (OX-40R), a member of the TNFR family, is primarily expressed
on activated CD4+ T lymphocytes. Engagement of the OX-40R, with either OX-40 ligand (OX …
on activated CD4+ T lymphocytes. Engagement of the OX-40R, with either OX-40 ligand (OX …
Vaccines for tumour prevention
Despite tremendous progress in basic and epidemiological research, effective prevention of
most types of cancer is still lacking. Vaccine use in cancer therapy remains a promising but …
most types of cancer is still lacking. Vaccine use in cancer therapy remains a promising but …
Trastuzumab increases HER2 uptake and cross-presentation by dendritic cells
VA Gall, AV Philips, NA Qiao, K Clise-Dwyer… - Cancer research, 2017 - AACR
Early-phase clinical trials evaluating CD8+ T cell–eliciting, HER2-derived peptide vaccines
administered to HER2+ breast cancer patients in the adjuvant setting suggest synergy …
administered to HER2+ breast cancer patients in the adjuvant setting suggest synergy …
DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice
The ability of vaccination with plasmids coding for the extracellular and the transmembrane
domain of the product of transforming rat Her-2/neu oncogene (r-p185) to protect against r …
domain of the product of transforming rat Her-2/neu oncogene (r-p185) to protect against r …
Targeting HER-2/neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion
BJ Czerniecki, GK Koski, U Koldovsky, S Xu, PA Cohen… - Cancer research, 2007 - AACR
Abstract Overexpression of HER-2/neu (c-erbB2) is associated with increased risk of
recurrent disease in ductal carcinoma in situ (DCIS) and a poorer prognosis in node-positive …
recurrent disease in ductal carcinoma in situ (DCIS) and a poorer prognosis in node-positive …
Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product
Y Oka, OA Elisseeva, A Tsuboi, H Ogawa, H Tamaki… - Immunogenetics, 2000 - Springer
The product of the Wilms' tumor gene WT1 is a transcription factor overexpressed not only in
leukemic blast cells of almost all patients with acute myeloid leukemia, acute lymphoid …
leukemic blast cells of almost all patients with acute myeloid leukemia, acute lymphoid …
Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy
LM Wood, Y Paterson - Frontiers in cellular and infection microbiology, 2014 - frontiersin.org
For over a century, inactivated or attenuated bacteria have been employed in the clinic as
immunotherapies to treat cancer, starting with the Coley's vaccines in the 19th century and …
immunotherapies to treat cancer, starting with the Coley's vaccines in the 19th century and …